ES2252554T3 - Pirimidotriacinas como inhibidores de fosfatasa. - Google Patents

Pirimidotriacinas como inhibidores de fosfatasa.

Info

Publication number
ES2252554T3
ES2252554T3 ES02805774T ES02805774T ES2252554T3 ES 2252554 T3 ES2252554 T3 ES 2252554T3 ES 02805774 T ES02805774 T ES 02805774T ES 02805774 T ES02805774 T ES 02805774T ES 2252554 T3 ES2252554 T3 ES 2252554T3
Authority
ES
Spain
Prior art keywords
ylmethyl
diamine
triazine
pyrimido
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02805774T
Other languages
English (en)
Spanish (es)
Inventor
Kevin Richard Guertin
Lina Quattrocchio Setti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2252554T3 publication Critical patent/ES2252554T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
ES02805774T 2001-12-27 2002-12-27 Pirimidotriacinas como inhibidores de fosfatasa. Expired - Lifetime ES2252554T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34393701P 2001-12-27 2001-12-27
US343937P 2001-12-27
US39911002P 2002-07-26 2002-07-26
US399110P 2002-07-26

Publications (1)

Publication Number Publication Date
ES2252554T3 true ES2252554T3 (es) 2006-05-16

Family

ID=26993696

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02805774T Expired - Lifetime ES2252554T3 (es) 2001-12-27 2002-12-27 Pirimidotriacinas como inhibidores de fosfatasa.

Country Status (19)

Country Link
US (1) US6642381B2 (enExample)
EP (1) EP1467996B1 (enExample)
JP (1) JP4188839B2 (enExample)
KR (1) KR100601769B1 (enExample)
CN (1) CN100402530C (enExample)
AT (1) ATE311388T1 (enExample)
AU (1) AU2002367190B2 (enExample)
BR (1) BR0215395A (enExample)
CA (1) CA2471265C (enExample)
DE (1) DE60207759T2 (enExample)
ES (1) ES2252554T3 (enExample)
JO (1) JO2242B1 (enExample)
MX (1) MXPA04006266A (enExample)
PA (1) PA8562901A1 (enExample)
PE (1) PE20030896A1 (enExample)
PL (1) PL371180A1 (enExample)
TW (1) TW200306313A (enExample)
UY (1) UY27606A1 (enExample)
WO (1) WO2003055883A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1439834A1 (en) * 2001-10-30 2004-07-28 Applied Research Systems ARS Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
PL377620A1 (pl) 2002-11-18 2006-02-06 F. Hoffmann-La Roche Ag Diazynopirymidyny
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
WO2005080346A1 (en) * 2004-02-12 2005-09-01 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1991544B1 (en) * 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010083645A1 (en) * 2009-01-21 2010-07-29 Shanghai Targetdrug Co., Ltd PYRIMIDO[5,4-e][1,2,4]TRIAZINES AND USES THEREOF
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
KR20150127599A (ko) 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
GB0022079D0 (en) 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor

Also Published As

Publication number Publication date
PA8562901A1 (es) 2003-07-28
DE60207759D1 (de) 2006-01-05
DE60207759T2 (de) 2006-08-03
EP1467996A1 (en) 2004-10-20
CA2471265A1 (en) 2003-07-10
JP4188839B2 (ja) 2008-12-03
TW200306313A (en) 2003-11-16
JO2242B1 (en) 2004-10-07
BR0215395A (pt) 2004-12-07
JP2005517677A (ja) 2005-06-16
KR20040068981A (ko) 2004-08-02
PE20030896A1 (es) 2003-11-05
ATE311388T1 (de) 2005-12-15
WO2003055883A1 (en) 2003-07-10
CN1610683A (zh) 2005-04-27
KR100601769B1 (ko) 2006-07-19
EP1467996B1 (en) 2005-11-30
US6642381B2 (en) 2003-11-04
AU2002367190B2 (en) 2006-10-05
UY27606A1 (es) 2003-06-30
US20030153756A1 (en) 2003-08-14
PL371180A1 (en) 2005-06-13
AU2002367190A1 (en) 2003-07-15
MXPA04006266A (es) 2004-09-27
CA2471265C (en) 2010-02-09
CN100402530C (zh) 2008-07-16

Similar Documents

Publication Publication Date Title
ES2336603T3 (es) Compuestos de pirido(2,3-d)pirimidina-2,4-diamina como inhibidores de ptp1b.
ES2315566T3 (es) Tiazolidin-4-onas para inhibir proteinas hyak3.
ES2915381T3 (es) Análogos de nucleótidos
EP1467996B1 (en) Pyrimidotriazines as phosphatase inhibitors
EP2010505B1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
ES2539478T3 (es) Inhibidores de PI3K/mTOR cinasa
ES2253881T3 (es) Inhibidores de quinasa dependiente de ciclinas.
ES2709034T3 (es) Pirimido[4,5-b]quinolina-4,5 (3h,10h)-dionas como supresores de mutaciones sin sentido
US20150320759A1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
ME02064B (me) Derivati kvinazolin-4(3h)-ona korisceni kao inhibitori pi3 kinaze
BRPI0718029A2 (pt) Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
IE910994A1 (en) Multi-functional pharmaceutical compounds and methods of use
US6197775B1 (en) Phosphonate nucleotide derivatives
US20240376076A1 (en) Inhibitors targeting ubiquitin specific protease 7 (usp7)
KR20190025545A (ko) 특정 단백질 키나제 억제제
EP1109814A1 (en) 5-heterocyclyl pyrazolo 4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
US20210070742A1 (en) Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
AU2003238915A1 (en) (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
US20040110775A1 (en) Cyclin dependent kinase inhibiting purine derivatives
US10800785B2 (en) Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors
ES2312968T3 (es) Compuestos novedosos.
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
RU2289583C2 (ru) Пиримидотриазины, способ их получения, фармацевтическая композиция на их основе и применение
CN1668288B (zh) 具有抗寄生虫活性的化合物和含有它们的药物
BG106811A (bg) Производни на захарин като орални активни инхибитори на еластаза